10-Q: CytoSorbents Q3 2025: Reduced Loss, Strategic Restructuring

CytoSorbents Corporation reported a significantly reduced net loss for the nine months ended September 30, 2025, driven by revenue growth and cost reductions, despite regulatory setbacks for DrugSorb-ATR and Nasdaq compliance concerns.

Summary

• Net loss for the nine months ended September 30, 2025, significantly improved to $2.7 million, compared to $13.2 million in the prior year.
• Revenue increased by 5.2% to $27.8 million for the nine months ended September 30, 2025, from $26.4 million in the prior year.
• Gross profit rose by 5.7% to $19.7 million for the nine months ended September 30, 2025, with gross margin remaining stable at 70.7%.
• Loss from operations improved by 20.6% to $10.4 million for the nine months ended September 30, 2025, compared to $13.1 million in the prior year.
• Research and development expenses decreased by 31.3% to $3.8 million for the nine months ended September 30, 2025, primarily due to the completion of the STAR-T clinical trial and reduced grant-funded projects.
• A strategic workforce and cost reduction plan was initiated on November 13, 2025, reducing the workforce by approximately 10% and realigning operating expenses, with an expected charge of up to $0.9 million.
• The company expects to reach operating cash flow break-even in the first quarter of 2026.
• FDA denied the De Novo request for DrugSorb-ATR, but affirmed no safety issues; a new De Novo application is expected to be filed in Q1 2026, with a regulatory decision anticipated in mid-2026.
• Health Canada also refused the Medical Device License application for DrugSorb-ATR; the company withdrew its reconsideration request and will resubmit after gaining clarity from the FDA.
• The company received a Nasdaq notification on October 2, 2025, for non-compliance with the minimum bid price requirement ($1.00 per share) and has a 180-day cure period until March 31, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern within twelve months after the financial statements' issuance date.
• A material weakness in internal control over financial reporting related to accounting for non-cash stock-based compensation for Restricted Stock Units was identified and is being remediated.

Sentiment

Score: 5

Explanation: The company shows improved financial performance and proactive cost-cutting measures, including a strategic workforce reduction, and has secured additional financing. However, significant regulatory hurdles for its key pipeline product (DrugSorb-ATR), ongoing Nasdaq listing compliance issues, and a stated 'going concern' doubt introduce substantial uncertainty and risk, balancing out the positive operational improvements.

Positives

• Net loss significantly improved to $2.7 million for the nine months ended September 30, 2025, from $13.2 million in the prior year.
• Loss from operations improved by 20.6% to $10.4 million for the nine months ended September 30, 2025.
• Total revenue increased by 5.2% to $27.8 million for the nine months ended September 30, 2025.
• Gross profit increased by 5.7% to $19.7 million, with gross margin remaining strong at 70.7% for the nine months ended September 30, 2025.
• Research and development expenses decreased by 31.3%, reflecting cost efficiencies and completion of the STAR-T clinical trial.
• Successful completion of a shareholder Rights Offering in January 2025, raising $5.4 million in net proceeds.
• Additional $1.4 million in net proceeds from the exercise of Series A Right Warrants in February 2025.
• Received $1.7 million from the New Jersey Technology Business Tax Certificate Transfer Program in April 2025.
• Amended Loan and Security Agreement provides access to an additional $2.5 million (Tranche 2a) in November 2025 and extends the interest-only period to December 31, 2026.
• Initiated a strategic workforce and cost reduction plan, expecting to reach operating cash flow break-even in Q1 2026.
• FDA affirmed no safety-related issues with the DrugSorb-ATR device despite the De Novo denial, proposing an expedited path forward for market authorization.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern within twelve months.
• FDA denied the De Novo request for DrugSorb-ATR, requiring a new application and delaying potential U.S. market approval.
• Health Canada refused the Medical Device License application for DrugSorb-ATR, leading to a withdrawal of reconsideration and delayed resubmission.
• Received a Nasdaq notification for non-compliance with the minimum bid price requirement ($1.00 per share), risking potential delisting.
• Identified a material weakness in internal control over financial reporting related to accounting for non-cash stock-based compensation for Restricted Stock Units.
• Net loss for the three months ended September 30, 2025, increased to $3.17 million from $2.77 million in the prior year, primarily due to a foreign currency transaction loss.
• Interest expense, net, increased to $1.87 million for the nine months ended September 30, 2025, from $0.78 million in the prior year.

Risks

• Uncertainty in obtaining FDA or Health Canada authorization and successful commercialization for DrugSorb-ATR in the U.S. or Canada.
• Failure to achieve market acceptance for CytoSorb, DrugSorb-ATR, or other products, which could prevent or delay revenue generation.
• Risk of delisting from the Nasdaq Stock Market LLC due to non-compliance with the minimum bid price requirement.
• Inability to secure additional funding on acceptable terms or at all, which could lead to slowing sales and marketing expansion, delaying regulatory approvals, or reducing headcount.
• Potential dilution to shareholders from the sale of additional equity securities.
• Fluctuations in foreign currency exchange rates can significantly impact financial results, as evidenced by the $9.1 million gain on foreign currency transactions for the nine months ended September 30, 2025, compared to $0.7 million in the prior year.

Future Outlook

The company expects to file a new De Novo application for DrugSorb-ATR with the FDA in the first quarter of 2026, with a regulatory decision anticipated in mid-2026. Following FDA clarity, a new Medical Device License application will be submitted to Health Canada. Management anticipates reaching operating cash flow break-even in the first quarter of 2026, supported by the strategic workforce and cost reduction plan. The company is actively monitoring its common stock price to regain Nasdaq compliance by March 31, 2026.

Management Comments

• We are making steady progress with the proactive reorganization and strategic realignment of our German commercial team and sales approach, tracking to expectations through the third quarter of 2025, and remain confident it will lead to stronger execution and improved performance in Germany and our financial results overall into next year.
• Upon approval, we expect to rapidly commercialize DrugSorb-ATR in the U.S. and Canada to address this large unmet medical need, with an initial estimated total addressable market of $300 million today to over $1 billion over time as we pursue additional indications.
• We believe that DrugSorb-ATR has the potential to become an all-in-one countermeasure for these agents.
• The Strategic Workforce and Cost Reduction Plan follows a comprehensive review of our cost structure and operating model, and we now expect that the Company will reach operating cash flow break-even in the first quarter of 2026.

Industry Context

CytoSorbents operates in the critical care and cardiac surgery medical device industry, specializing in blood purification technologies. Its lead product, CytoSorb, is approved in the EU and distributed in over 70 countries, addressing conditions like sepsis, burn injury, and liver failure. The investigational DrugSorb-ATR system aims to reduce perioperative bleeding in high-risk surgery, targeting a significant unmet medical need in the U.S. and Canada. The company's focus on innovative polymer-based adsorption technology positions it within a niche but high-impact segment of the medical device market, where effective treatments for life-threatening conditions are often limited.

Corporate Governance

Legal Proceedings

• The company is subject to claims and litigation arising in the ordinary course of business but is not currently a party to any litigation or legal proceedings likely to have a material adverse effect on its business.

Related Party Transactions

• Management and the Board of Directors subscribed for approximately 450,000 of the total Units in the Rights Offering.
• Members of management and the Board of Directors exercised approximately 1.4 million Series A Right Warrants.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity offerings, risk of Nasdaq delisting, and uncertainty regarding the company's going concern status. However, they could benefit from improved financial performance and successful DrugSorb-ATR commercialization.
• **Employees**: Approximately 10% of the workforce was reduced as part of the Strategic Workforce and Cost Reduction Plan, impacting those employees directly.
• **Customers**: Continued availability of CytoSorb in existing markets and potential future access to DrugSorb-ATR in the U.S. and Canada, pending regulatory approvals, could benefit patients and healthcare providers.
• **Creditors (Avenue Capital Group)**: The Amended Loan and Security Agreement provides additional funding tranches and extends interest-only periods, but also includes new warrants and cash burn targets, impacting their risk exposure and potential returns.
• **Regulatory Bodies (FDA, Health Canada)**: The company's ongoing interactions and resubmissions for DrugSorb-ATR demonstrate continued engagement with regulatory processes, which could lead to new product approvals.

Next Steps

• File a new De Novo application for DrugSorb-ATR with the FDA in Q1 2026.
• Anticipate a formal meeting with the FDA in late Q4 2025 or early 2026 to confirm requirements for the new De Novo submission.
• Expect a regulatory decision from the FDA on DrugSorb-ATR in mid-2026.
• Resubmit a new Medical Device License application to Health Canada for DrugSorb-ATR after gaining better visibility from the FDA.
• Actively monitor the common stock's closing bid price and consider options to regain Nasdaq compliance by March 31, 2026.
• Achieve operating cash flow break-even in the first quarter of 2026.
• Implement measures to strengthen internal control over financial reporting, with enhancements expected to be fully implemented during the fiscal year ending December 31, 2025.
• Maintain certain operating cash burn targets prior to FDA approval of DrugSorb-ATR as required by the Amended Loan and Security Agreement.

Key Dates

Recommendation

While CytoSorbents has demonstrated improved financial performance, including a significantly reduced net loss and increased revenue, alongside proactive cost-cutting measures and successful capital raises, several critical uncertainties warrant a 'hold' recommendation. The 'going concern' doubt, the Nasdaq minimum bid price non-compliance, and the regulatory setbacks for the pivotal DrugSorb-ATR device in both the U.S. and Canada introduce substantial risk. The potential for future dilution from capital raises and the identified material weakness in internal controls further contribute to a cautious outlook. Investors should monitor progress on DrugSorb-ATR regulatory approvals, Nasdaq compliance, and the achievement of cash flow break-even before considering a stronger position.

Keywords

CytoSorbents, DrugSorb-ATR, blood purification, medical devices, SEC filing, 10-Q, financial results, Q3 2025, FDA approval, Nasdaq listing, capital raise, cost reduction, going concern, critical care, cardiac surgery, sepsis, antithrombotic removal